Br J Haematol. IL-6 blockade treatment for severe COVID-19 in two patients with multiple myeloma

[tetano]

Br J Haematol. 2020 May 5. doi: 10.1111/bjh.16787. [Epub ahead of print]
IL-6 blockade treatment for severe COVID-19 in two patients with multiple myeloma.


Chaidos A¹, Katsarou A¹, Mustafa C¹, Milojkovic D², Karadimitris A¹.

Author information




Abstract

Coronavirus disease 2019 (COVID-19) presents with a broad clinical spectrum, varying from asymptomatic infection to severe pneumonitis, leading to acute respiratory distress syndrome (ARDS) and death(Guan, et al 2020). Accumulating evidence suggests that in severe COVID-19, an acute hyperinflammatory syndrome characterised by fever, hypoxia and increased serum inflammatory markers, occurring 5-10 days from the first symptoms, is the major driver of morbidity and death(Zhou, et al 2020b). Hyperinflammation is not specific to COVID-19. Similar syndromes were previously described in respiratory disease associated with other coronaviruses, including the severe acute respiratory syndrome-coronavirus (SARS-CoV) in 2003 and Middle East respiratory syndrome-coronavirus (MERS-CoV) in 2012(Castilletti, et al 2005, Tseng, et al 2005).
This article is protected by copyright. All rights reserved.



PMID:32369612DOI:10.1111/bjh.16787